Fat-reducing and anti-lipogenic composition containing vesicle-containing spheres of egcg and fermented red ginseng and preparation method thereof

Abstract

The application discloses a kind of fat-reducing anti-lipogenesis compositions containing vesicle ball EGCG and fermented red ginseng, including core active ingredient, active additive ingredient and auxiliary active ingredient, the raw material of the core active ingredient includes vesicle ball EGCG and red ginseng fermentation liquor, the active additive ingredient is fermented red ginseng powder, the auxiliary active ingredient includes coffee powder, medium-chain triglyceride powder, L-arabinose and white kidney bean extract, the vesicle ball EGCG delivery system is structured by vesicle ball EGCG and red ginseng fermentation liquor in the application, the problem of poor stability and difficult absorption of EGCG is solved, efficient protection and targeted delivery of EGCG are realized, component delivery is realized by "fat decomposition-energy metabolism-oxidative stress regulation" multi-target mechanism, and the metabolism improvement rate and fat inhibition rate are significantly improved, and the effect of fat reduction and anti-lipogenesis is obviously improved.

Description

Technical Field

[0001] This invention belongs to the technical field of EGCG-containing weight loss compositions, specifically relating to a weight loss and anti-fat generation composition containing EGCG vesicles and fermented red ginseng, and its preparation method. Background Technology

[0002] Activating the UCP-1 (uncoupling protein 1) thermogenesis pathway in brown adipose tissue (BAT) is a key direction for achieving efficient fat loss. Under UCP-1 mediation, protons can penetrate across the mitochondrial inner membrane, uncoupling oxidative phosphorylation and releasing energy as heat rather than ATP synthesis. This pathway can directly "burn" fat to generate heat, fundamentally increasing energy expenditure. Previous studies have shown that epigallocatechin gallate (EGCG) can effectively regulate brown adipose tissue thermogenesis. EGCG is a major catechin compound in tea. However, EGCG suffers from poor water solubility, easy oxidative degradation, and low bioavailability. Furthermore, the fat-loss effect of a single component is limited. This may be because most existing UCP-1 channel-mediated weight loss products rely on a single component acting on a specific link in the metabolic pathway, resulting in limited effectiveness, easy "drug resistance," low bioavailability, and poor stability, making it difficult to effectively activate this core pathway.

[0003] Traditional evaluations of the weight-loss efficacy of fat-reducing health foods and drugs primarily rely on animal models, such as mouse experiments. These methods involve feeding mice with a diet or administering the drug via gavage, and determining the fat-reducing effect by measuring initial and final mouse weight or changes in appetite-related hormone levels. This evaluation method mainly depends on food utilization or body fat weight, failing to directly reflect the dynamics of fat metabolism. Furthermore, this approach struggles to sensitively capture localized fat changes, resulting in poor accuracy for evaluating multi-mechanism, long-term health foods and drugs (such as those simultaneously promoting fat breakdown and inhibiting absorption). The zebrafish weight-loss model effectively overcomes these shortcomings. Zebrafish possess a digestive system similar to humans, and their yolk sac contains 70% neutral fat. The absorption-promoting effect on the yolk sac can visually demonstrate fat breakdown and metabolism. In his paper "Study on the Weight Loss Effect of Eel Peptide Based on Zebrafish Model", Guan Tianzhu disclosed a technical solution for studying the weight loss effect of eel peptide using zebrafish as a model organism. The solution can intuitively reflect the fat decomposition and metabolism by observing the intensity of the fluorescence signal of fat in the yolk sac, intestine and tail blood vessels of zebrafish.

[0004] Providing a stable delivery system for EGCG-containing health food products with high bioavailability and multi-target synergistic targeting of active ingredients in the UCP-1 pathway to achieve significant fat breakdown and metabolism is an effective way to achieve the evolution of the next generation of fat reduction products. Summary of the Invention

[0005] The technical problem to be solved by this invention is to address the shortcomings of the prior art by providing a fat-reducing and fat-anti-fat-generating composition containing vesicular EGCG and fermented red ginseng, and its preparation method. This fat-reducing and fat-anti-fat-generating composition includes a core active ingredient, an active additive ingredient, and auxiliary active ingredients. The raw materials for the core active ingredient include vesicular EGCG and red ginseng fermentation broth. The active additive ingredient is fermented red ginseng powder. The auxiliary active ingredients include coffee powder, medium-chain triglyceride powder, L-arabinose, and white kidney bean extract. Through a vesicular EGCG delivery system constructed with vesicular EGCG and red ginseng fermentation broth, highly efficient protection and targeted delivery of EGCG are achieved, overcoming the core defect of insufficient EGCG bioavailability. The active ingredients in the composition exhibit deep synergy in upstream pathways such as AMPK / PGC-1α. Under the overall metabolic environment of the microenvironment formed by the auxiliary active ingredients, an optimal cellular signaling environment is created for activating UCP-1, strongly and persistently activating UCP-1 protein expression, truly transforming adipose tissue into a sustained thermogenic "fat-burning engine."

[0006] To solve the above-mentioned technical problems, the technical solution adopted by the present invention is as follows: On the one hand, a fat-reducing and fat-resistant composition containing vesicular EGCG and fermented red ginseng is provided, comprising a core active ingredient, an active additive ingredient, and an auxiliary active ingredient. The raw materials of the core active ingredient include vesicular EGCG and fermented red ginseng broth. The active additive ingredient is fermented red ginseng powder. The auxiliary active ingredients include coffee powder, medium-chain triglyceride powder, L-arabinose, and white kidney bean extract.

[0007] Furthermore, a method for preparing the above-mentioned fat-reducing and fat-anti-fat-forming composition containing vesicular EGCG and fermented red ginseng is provided, comprising: Step 1: Provide fermented red ginseng powder and red ginseng fermentation liquid; Step 2: Combine EGCG vesicles with red ginseng fermentation liquid to form core active ingredient granules; Step 3: Mix the core active ingredient granules, active additives and auxiliary active ingredients to obtain a fat-reducing and fat-resistant composition containing EGCG vesicles and fermented red ginseng.

[0008] Compared with the prior art, the present invention has the following advantages: 1. This invention provides a fat-reducing and anti-lipidogenesis composition containing vesicular EGCG and fermented red ginseng. By constructing a vesicular EGCG delivery system using vesicular EGCG and fermented red ginseng broth, it specifically addresses the problems of poor EGCG stability and difficult absorption, achieving efficient protection and targeted delivery of EGCG. Through a multi-target mechanism of action involving "lipolysis-energy metabolism-oxidative stress regulation," it strongly and synergistically activates the uncoupling protein-1 (UCP-1) thermogenic pathway, systematically solving the key bottlenecks of low bioavailability and single-function of traditional ingredients, and exhibiting significant fat-reducing and anti-lipidogenesis effects.

[0009] 2. This invention provides a method for preparing a fat-reducing and fat-resistant composition containing EGCG vesicles and fermented red ginseng. The method enhances the effect of active ingredients through physical vesicle formation and biological fermentation, without the need for chemical modification of active ingredients or introduction of synthetic additives. The product composition has less irritation to the gastrointestinal tract and reduces the occurrence of side effects.

[0010] 3. This invention focuses on precise metabolic regulation and achieves efficient activation of the UCP-1 pathway through multi-component synergy, realizing a technological leap from "component superposition" to "system enhancement". It provides a clear scientific path and solution for developing efficient and safe next-generation weight loss products. It not only solves the technical defects of single components, but also builds a scientific, complete, verifiable and industrializable weight loss enhancement system.

[0011] 4. The preparation method of the present invention is simple and easy to scale up for production. The product composition is in powder form and can be adapted to the production of various dosage forms such as capsules, tablets, oral liquids, and solid beverages without the need for additional adjustments to production equipment.

[0012] The technical solution of the present invention will be further described in detail below with reference to the accompanying drawings and embodiments. Attached Figure Description

[0013] Figure 1 This is a schematic diagram of the fluorescence intensity of zebrafish yolk sac fat after treatment with the composition of the present invention; Figure 2 This is a schematic diagram illustrating the effect of the composition of the present invention on promoting fat decomposition; Figure 3 This is a schematic diagram showing the staining intensity of zebrafish fat after treatment with the composition of the present invention; Figure 4 This is a schematic diagram illustrating the effect of the composition of the present invention in inhibiting fat synthesis; Figure 5 The vesicle morphology of the core active ingredient granules in Examples 1 and 3 of the present invention is shown. Detailed Implementation

[0014] The technical solution will now be clearly and completely described with reference to the embodiments of this application. Obviously, the described embodiments are only a part of the embodiments of this application, not all of them. All other embodiments obtained by those skilled in the art based on the embodiments of this application without creative effort are within the scope of protection of this application.

[0015] In the following description, the term "and / or" is used to describe the relationship between related objects, indicating that there can be three relationships. For example, A and / or B can mean: A exists alone, B exists alone, and A and B exist simultaneously. A and B can be singular or plural.

[0016] In the following description, the terms “including,” “containing,” “having,” and “containing” are open-ended terms, meaning that they include but are not limited to.

[0017] Those skilled in the art should understand that, in the following description of the embodiments of this application, the sequence of numbers does not imply the order of execution. Some or all steps may be executed in parallel or sequentially. The execution order of each process should be determined by its function and internal logic, and should not constitute any limitation on the implementation process of the embodiments of this application.

[0018] Those skilled in the art will understand that the numerical ranges in the embodiments of this application should be understood to specifically disclose each intermediate value between the upper and lower limits of the range. Each smaller range between any stated value or intermediate value within a stated range, and any other stated value or intermediate value within said range, is also included in this application. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.

[0019] Unless otherwise stated, the technical / scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application pertains. While this application describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may be used in the implementation or testing of this application. All references to this specification are incorporated by way of citation to disclose and describe methods and / or materials associated with those references. In the event of any conflict with any incorporated reference, the content of this specification shall prevail.

[0020] The technical principle employed in this invention is based on precise metabolic regulation, constructing a complete multi-component synergistic formulation system. It uses vesicle-globulized epigallocatechin gallate (EGCG) as the highly efficient delivery core, synergistically combining fermented red ginseng powder and auxiliary active ingredients. Through a multi-target mechanism, it powerfully and synergistically activates the uncoupling protein-1 (UCP-1) thermogenic pathway, systematically addressing the key bottlenecks of low bioavailability and singular function of traditional components. This achieves weight loss, improves basal insulin sensitivity, and lowers blood lipid levels, while simultaneously achieving fat breakdown and preventing metabolic disorders, demonstrating significant fat reduction and anti-lipidogenesis effects.

[0021] On the one hand, a fat-reducing and fat-resistant composition containing vesicular EGCG and fermented red ginseng is provided, comprising a core active ingredient, an active additive ingredient, and an auxiliary active ingredient. The raw materials of the core active ingredient include vesicular EGCG and fermented red ginseng broth. The active additive ingredient is fermented red ginseng powder. The auxiliary active ingredients include coffee powder, medium-chain triglyceride powder, L-arabinose, and white kidney bean extract.

[0022] This invention provides a fat-reducing and fat-resistant composition containing vesicular EGCG and fermented red ginseng, comprising a core active ingredient, an active additive, and an auxiliary active ingredient. The raw materials of the core active ingredient include vesicular EGCG and red ginseng fermentation broth, and the active additive is fermented red ginseng powder. Through a vesicular EGCG delivery system constructed with vesicular EGCG and red ginseng fermentation broth, efficient protection and targeted delivery of EGCG are achieved. EGCG is responsible for initiating the thermogenic process, while the red ginseng fermentation broth and fermented red ginseng powder enhance mitochondrial function and reduce inflammatory interference. The auxiliary active ingredient maintains the homeostasis of energy metabolism. Together, they form a complete "initiation-amplification-maintenance" action chain.

[0023] In some embodiments, the mass ratio of the core active ingredient, the active additive ingredient, and the auxiliary active ingredient is 1:0.5 to 1:2 to 4; preferably, the mass ratio of the core active ingredient, the active additive ingredient, and the auxiliary active ingredient is 1:0.7 to 0.8:2.5 to 2.7.

[0024] On the other hand, a method for preparing the above-mentioned fat-reducing and fat-anti-lipid formation composition containing vesicular EGCG and fermented red ginseng is provided, comprising: Step 1: Provide fermented red ginseng powder and red ginseng fermentation liquid; Step 2: Combine EGCG vesicles with red ginseng fermentation liquid to form core active ingredient granules; Step 3: Mix the core active ingredient granules, active additives and auxiliary active ingredients to obtain a fat-reducing and fat-resistant composition containing EGCG vesicles and fermented red ginseng.

[0025] This invention provides a method for preparing the above-mentioned fat-reducing and anti-lipid formation composition containing vesicular EGCG and fermented red ginseng. By providing fermented red ginseng powder and red ginseng fermentation liquid, vesicular EGCG is combined with red ginseng fermentation liquid to form vesicular epigallocatechin gallate (EGCG), which serves as a highly efficient delivery core. In synergy with the active additive fermented red ginseng powder and auxiliary active ingredients, a composition with significant fat-reducing and anti-lipid formation effects is constructed.

[0026] In some embodiments, the preparation method of the red ginseng fermentation liquid includes: dispersing red ginseng powder in water, fermenting it after enzymatic hydrolysis with a compound enzyme to obtain red ginseng fermentation liquid; the preparation method of the fermented red ginseng powder includes: spray drying the red ginseng fermentation liquid to obtain fermented red ginseng powder.

[0027] In some embodiments, the mass ratio of red ginseng powder, water, and compound enzyme is (1~2):(6~8):(0.1~0.15); the compound enzyme is cellulase and pectinase, and the mass ratio of cellulase and pectinase is (0.05~0.08):(0.05~0.07); preferably, the mass ratio of cellulase and pectinase is 1:1.

[0028] In some embodiments, the enzymatic hydrolysis temperature of the complex enzyme is 48℃~52℃, and the hydrolysis time is 5h~6h.

[0029] In some embodiments, the fermentation includes mixing the system to be fermented with lactic acid bacteria, first sealing and stirring, then allowing it to stand; the lactic acid bacteria are *Lactobacillus plantarum* (HCS03-001) and *Lactobacillus fermentatus* (HCS08-005), wherein the mass of *Lactobacillus plantarum* is 8%~9% of the mass of water, and the mass of *Lactobacillus fermentatus* is 8%~9% of the mass of water. In some embodiments, the sealing and stirring time is 15 min, the fermentation temperature is 36.5℃~37.5℃, the standing time is 16 h~24 h, and the fermentation endpoint is a system pH of 3.50~3.90.

[0030] In some embodiments, step two, combining EGCG vesicles with the fermented red ginseng to form core active ingredient granules, specifically includes: EGCG, maltodextrin, and β-cyclodextrin were added to the red ginseng fermentation broth, mixed well, and then pre-filtered and filtered through a double-layer filter membrane to obtain a mixed solution. After spray drying, the core active ingredient granules were obtained.

[0031] In some embodiments, the pre-filter membrane has a pore size of 0.45 μm, and the double-layer filter membrane has pore sizes of 0.45 μm and 0.22 μm, respectively.

[0032] In some embodiments, the mass ratio of the red ginseng fermentation liquid, EGCG, maltodextrin and β-cyclodextrin is (87~82):(4~6):(4~5):(5~7).

[0033] The above-mentioned mass ratio of red ginseng fermentation broth, EGCG, maltodextrin, and β-cyclodextrin can effectively construct the core active ingredient granules, forming a highly efficient delivery system for vesicular EGCG. When combined with fermented red ginseng powder, the vesicular EGCG enhances UCP-1 gene expression. The core active ingredient and the added active ingredients, along with the transgenic saponins (such as Rg3 and Rh2) from fermented red ginseng, work together to enhance UCP-1 protein activity, dually targeting the thermogenesis pathway in brown adipose tissue, and achieving a simultaneous increase in fat decomposition rate and energy conversion efficiency.

[0034] In some embodiments, step three, mixing the core active ingredient granules, active additives, and auxiliary active ingredients to obtain a fat-reducing and fat-resistant composition containing EGCG vesicles and fermented red ginseng, specifically includes: (1) Mix the core active ingredient granules and the active additives to obtain mixed granules; (3) Add the mixed granules into the auxiliary active ingredients and mix well to obtain a fat-reducing and fat-resistant composition containing EGCG vesicles and fermented red ginseng; the mixing is achieved by adding the ingredients in equal increments and stirring three times, and stirring for 15 minutes after each addition.

[0035] The raw materials in this invention include fermented red ginseng powder and red ginseng fermentation liquid. The whole fermentation technology solves the problem of low utilization rate of traditional red ginseng saponins. By constructing EGCG vesicles and adding them as active ingredients, an active form that is more easily absorbed by the human body is formed, and the bioavailability of active ingredients is higher. This overcomes the defects of natural raw materials with high content of effective ingredients but low in vivo efficacy.

[0036] In some embodiments, the mass ratio of the core active ingredient granules to fermented red ginseng powder is (4~8):(3~6).

[0037] In some embodiments, the mass ratio of coffee powder, medium-chain triglyceride powder, L-arabinose, and white kidney bean extract in the auxiliary active ingredients is (6~7):(4~6):(3~5):(3~5).

[0038] To enable those skilled in the art to better understand the present invention, the technical solutions of the present invention will be clearly and completely described below with reference to the accompanying drawings of the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort should fall within the scope of protection of the present invention.

[0039] Unless otherwise specified, the raw materials or chemical reagents used in the embodiments of this invention are obtained through conventional commercial channels.

[0040] Sources of some raw materials: EGCG: Shaanxi Angxu (Angsheng) Biotechnology Co., Ltd.; Red ginseng: All are raw materials harvested from ginseng (artificially cultivated for 5 years or less); Coffee powder: Yunnan Cold Brew Technology Co., Ltd.; Medium-chain triglyceride powder: Dalian Yinuo Biotechnology Co., Ltd.; White kidney bean extract: Zhongbai Xingye Food Technology (Beijing) Co., Ltd.; Model: Water-soluble WXLJ-4002; Arabic sugar: Shandong Lvjian Biotechnology Co., Ltd.; Cellulase: Danisco, Model: Viscozyme L, Activity: 1000 U / mL; Pectinase: Danisco, Model: Pectinase Y-23, Activity: 15000 U / mL.

[0041] Example 1 This embodiment provides a fat-reducing and fat-resistant composition containing EGCG vesicles and fermented red ginseng, including a core active ingredient, an active additive, and an auxiliary active ingredient. The raw materials of the core active ingredient include EGCG vesicles and fermented red ginseng broth. The active additive is fermented red ginseng powder. The auxiliary active ingredients include coffee powder, medium-chain triglyceride powder, L-arabinose, and white kidney bean extract.

[0042] This embodiment also provides a method for preparing the above-mentioned fat-reducing and fat-anti-fat-forming composition containing vesicular EGCG and fermented red ginseng, comprising: Step 1: Provide fermented red ginseng powder and red ginseng fermentation liquid; Step 2: Combine EGCG vesicles with red ginseng fermentation liquid to form core active ingredient granules; Step 3: Mix the core active ingredient granules, active additives and auxiliary active ingredients to obtain a fat-reducing and fat-resistant composition containing EGCG vesicles and fermented red ginseng.

[0043] The specific preparation method is as follows: Step 1: Provide fermented red ginseng, including: (1) Add 1 kg of red ginseng powder and 6 kg of drinking water to a fermentation tank and stir evenly. Then add 0.05 kg of cellulase and 0.05 kg of pectinase and raise the temperature to 50°C for enzymatic hydrolysis for 5 hours. (2) Centrifuge the system after enzymatic hydrolysis in step (1) at room temperature, and sterilize the supernatant. At this time, the solid content is 12.9 Brix and the pH is 4.5. The centrifugation rate is 5000 r / min and the centrifugation time is 10 min. (3) Add 0.48 kg of plant lactobacillus (HCS03-001) and 0.54 kg of fermenting mucin lactobacillus (HCS08-005) to the fermentation tank. The temperature of the fermentation tank is controlled at 37℃. The supernatant after sterilization in step (2) is inoculated into the fermentation tank. After sealing and stirring for 15 min, it is allowed to stand for fermentation for 20 h until the pH is 3.60. (4) The fermented system obtained in step (3) is centrifuged at 4200 r / min for 15 min at 4℃ to remove cell debris, and the fermentation supernatant is filtered through a 0.45 μm filter membrane to obtain red ginseng fermentation liquid; the concentration of fermented red ginseng in the red ginseng fermentation liquid is about 13 wt%. (5) Take a portion of the red ginseng fermentation liquid and spray dry it for 15 seconds at a feed rate of 10 ml / min, with an air inlet temperature of 170°C and a nozzle temperature of 85°C to obtain fermented red ginseng powder. Step 2: Combine EGCG vesicles with the fermented red ginseng to form core active ingredient granules, specifically including: (1) Add 8.5 kg of the red ginseng fermentation liquid to a mixing tank and stir evenly. Then add 0.5 kg of EGCG, 0.5 kg of maltodextrin and 0.5 kg of β-cyclodextrin in sequence. Raise the temperature to 60°C and stir for 10 min to fully encapsulate the ginseng. Then cool. (2) The cooled system is first pre-filtered through a 0.45μm filter membrane, and then transported to a temporary storage tank through a peristaltic pump via a 0.45μm+0.22μm double-layer filter membrane. The temperature of the temporary storage tank is room temperature. (3) Connect the outlet of the temporary storage tank to the spray drying tower, and perform spray drying for 15s at a feed rate of 10ml / min, with an air inlet temperature of 170℃ and a nozzle temperature of 85℃ to obtain the core active ingredient granules. Step 3: Mix the core active ingredient granules, active additives, and auxiliary active ingredients to obtain a fat-reducing and fat-resistant composition containing EGCG vesicles and fermented red ginseng, specifically including: (1) Mix 6 kg of the core active ingredient granules and 4.5 kg of the fermented red ginseng powder to obtain mixed granules; (2) Add 6 kg of weighed coffee powder, 4 kg of medium-chain triglyceride powder, 3 kg of L-arabinose and 3 kg of white kidney bean extract into a small three-dimensional mixing container in sequence, shake well for 15 min, mix evenly, and obtain a mixture of auxiliary active ingredients. (3) The mixed granules are added to the auxiliary active ingredient mixture in equal increments in three batches. After each addition, the mixture is stirred for 15 minutes to ensure thorough mixing and obtain a fat-reducing and fat-resistant composition containing EGCG vesicles and fermented red ginseng. (4) Disassemble and seal the mixed product obtained in step (3).

[0044] Comparative Example 1 (Unvested EGCG + Unfermented Red Ginseng Powder) This comparative study examines the effect of EGCG vesicles on product performance and provides a method for preparing the composition, including: (1) Mix 6 kg of EGCG and 4.5 kg of red ginseng powder to obtain system A; (2) Add 6 kg of coffee powder, 4 kg of medium-chain triglyceride powder, 3 kg of L-arabinose and 3 kg of white kidney bean extract into a small three-dimensional mixing container in sequence, shake for 15 min, mix evenly, and obtain system B; (3) Using the same incremental method as in Example 1, system A was added to system B to obtain the composition, which was then packaged and sealed.

[0045] Comparative Example 2 (unvesicle-sized EGCG) This comparative study examines the effects of fermentation and EGCG vesicle formation on product properties and provides a method for preparing the composition, including: (1) Mix 6 kg of EGCG and 4.5 kg of fermented red ginseng powder to obtain system A; the fermented red ginseng powder is the fermented red ginseng powder prepared according to Example 1; (2) Add 6 kg of coffee powder, 4 kg of medium-chain triglyceride powder, 3 kg of L-arabinose and 3 kg of white kidney bean extract into a small three-dimensional mixing container in sequence, shake for 15 min, mix evenly, and obtain system B; (3) Using the same incremental method as in Example 1, system A was added to system B to obtain the composition, which was then packaged and sealed.

[0046] Comparative Example 3 (Unfermented Red Ginseng Powder) This comparative study examines the effect of compatibility on product performance and provides a method for preparing the composition, including: (1) Add 1 kg of red ginseng powder and 6 kg of drinking water to a mixing tank and stir evenly. Then add 0.5 kg of EGCG, 0.5 kg of maltodextrin and 0.5 kg of β-cyclodextrin in sequence. Raise the temperature to 60°C, stir for 10 min and then cool. (2) After cooling in step (1), the system is first pre-filtered through a 0.45μm filter membrane, and then transported to a temporary storage tank through a peristaltic pump via a 0.45μm+0.22μm double-layer filter membrane. The temperature of the temporary storage tank is room temperature. (3) Connect the outlet of the temporary storage tank to the spray drying tower, and perform spray drying for 15s at a feed rate of 10ml / min, with an air inlet temperature of 170℃ and a nozzle temperature of 85℃ to obtain the core active ingredient granules. (4) Mix 6 kg of the core active ingredient granules and 4.5 kg of red ginseng powder to obtain system A; (5) Add 6 kg of coffee powder, 4 kg of medium-chain triglyceride powder, 3 kg of L-arabinose and 3 kg of white kidney bean extract into a small three-dimensional mixing container in sequence, shake well for 15 min, mix evenly, and obtain system B; (6) Using the same incremental method as in Example 1, system A was added to system B to obtain the composition, which was then packaged and sealed.

[0047] Performance testing (1) Promotes fat decomposition and metabolism The fat-promoting metabolic properties of the compositions in the various embodiments and comparative examples were tested as follows: 1. Testing materials 1.1 Sample preparation: Compositions of each embodiment and comparative example.

[0048] 1.2 Experimental animals: All zebrafish are raised in aquarium water at 28 ℃ (water quality: conductivity 500~800 μS / cm; pH 7.0~8.0), bred and provided by our aquarium center. They are AB strain zebrafish and are bred through natural pair mating.

[0049] 1.3 Instruments, Consumables and Reagents: Fluorescence microscope; electronic analytical balance; 6-well plate, dropper; egg yolk powder.

[0050] 2. Detection method: 2.1 Sample efficacy MTC determination AB strain zebrafish, 24 hpf post-fertilization, were randomly selected and placed in 6-well plates, with 30 zebrafish treated in each group (experimental group). The test samples were administered in water-soluble form (sample concentrations are shown in Table 1). A blank control group and sample exposure groups with varying concentrations were set up. 3 mL of sample was administered to each well, and the plates were incubated in a 28 ℃ light incubator for 48 h. Mortality was recorded for each group. The blank control group received no sample, only the same volume of E3 culture medium. The drug concentration was determined based on the maximum safe dose for zebrafish.

[0051] Evaluation indicator: Mortality rate.

[0052] 2.2 Effects of the sample on promoting lipid catabolism Experimental groups: Control group, Positive drug group, Example 1, Comparative Example 1, a total of 4 groups.

[0053] Experimental Methods: Wild-type AB strain zebrafish at 48 hpf were randomly selected and divided into two groups of 10 each. The test samples were administered in water-soluble form (the concentration of the samples in the experimental groups was 100 μg / mL) and positive control drugs. The control group was given E3 culture medium at the same concentration of 100 μg / mL, and the positive control group was given simvastatin at the same concentration of 100 μg / mL. After treatment for 1 day, Nile red dye was administered in water-soluble form, and treatment continued until 4 dpf. Images of the yolk sac of zebrafish in each group were acquired by fluorescence microscopy, and the fluorescence intensity was counted to evaluate the efficacy of the samples in promoting lipolysis.

[0054] 3. Test Results 3.1 Sample efficacy MTC determination Table 1. Experimental results of MTC determination of samples (n = 30)

[0055] Table 1 shows the results of the MTC determination experiment for the sample efficacy. It can be seen that under the experimental conditions, no mortality was observed in the normal control group zebrafish, mortality occurred in the sample group with a concentration ≥200 μg / mL, and no phenotypic abnormalities were observed in the sample group with a concentration ≤100 μg / mL, indicating that the MTC was 100 μg / mL. Comparative Example 1 used the same concentration for the experiment, and the results are shown in Table 1; no phenotypic abnormalities were observed.

[0056] 3.2 Effects of the sample on promoting fat catabolism Table 2. Results of experiments promoting fat catabolism (n = 10)

[0057] Compared with the model control group,

[0058] Depend on Figure 1 , Figure 2As shown in Table 2, under the experimental conditions, at a concentration of 100 μg / mL, compared with the normal control group, the fluorescence signal intensity of yolk sac fat in the experimental group was significantly reduced, indicating a significant promotion of fat decomposition (p<0.001). This demonstrates that the composition containing vesicular EGCG and fermented red ginseng powder prepared in this invention has a significant advantage in promoting fat decomposition. At the same concentration, the metabolic enhancement rate of Example 1 was 44.19%, while that of Comparative Example 1 was only 24.96%, Comparative Example 2 was only 28.48%, and Comparative Example 3 was only 33.09%. The effect of Example 1 in promoting fat decomposition was superior to that of the comparative examples. The metabolic enhancement rate of Example 1 was significantly better than that of the positive control group, while the metabolic enhancement rate of Comparative Example 1 was only 24.96%, which was less effective than that of the positive control group.

[0059] This experiment, through a fat-promoting performance test, demonstrated that the fat-promoting composition prepared in this invention, containing EGCG vesicles and fermented red ginseng powder with synergistic effects, has a strong weight-loss ability, and its fat-promoting effect is superior to that of Comparative Example 1 and the positive control group. This provides strong experimental support for the application of this fat-reducing functional drink in the field of slimming, indicating that it helps people lose weight and manage their body shape by promoting fat decomposition.

[0060] (2) Inhibits fat synthesis The fat absorption-inhibiting properties of the synergistic fat-reducing and weight-loss coffee functional beverage containing vesicular EGCG and fermented red ginseng powder prepared in Example 1, and the EGCG and red ginseng powder compound preparation prepared in Comparative Example 1 were tested as follows: Experimental groups: Control group, Model group, Example 1, Comparative Example 1, a total of 4 groups.

[0061] Experimental methods: Wild-type AB strain zebrafish with a 5dpf growth rate were randomly selected and randomly divided into groups. The MTC obtained from the above test was administered to the samples in water-soluble form. After treatment for 1 hour, except for the control group, all samples were given egg yolk powder to establish a fat absorption model. The treatment was continued until 9dpf. The zebrafish were collected and stained with Oil Red O. Images of zebrafish in each group were collected by fluorescence microscopy. The staining intensity of fat in the intestinal and tail blood vessels was counted to evaluate the efficacy of the samples in inhibiting fat synthesis.

[0062] 3. Test Results Table 3. Results of experiments on inhibiting fat synthesis (n = 10)

[0063] Compared with the model control group,

[0064] Depend on Figure 3 , Figure 4As shown in Table 3, under the experimental conditions, compared with the model control group, Example 1 showed a significant decrease in the intensity of fat staining in the intestines and tail vessels of zebrafish at a concentration of 100 μg / mL, demonstrating a significant effect in inhibiting fat synthesis (p<0.001). At the same concentration, Example 1 showed a fat inhibition rate of 36.39%, Comparative Example 1 was 30.52%, Comparative Example 2 was 31.99%, and Comparative Example 3 was 34.68%, which was superior to the Comparative Example.

[0065] This experiment, through a fat-inhibiting performance test, demonstrated that the coffee prepared in this invention, containing EGCG vesicles and fermented red ginseng powder, has a strong ability to inhibit fat pushing, and its fat inhibition rate is better than that of the product in Comparative Example 1. This provides strong experimental support for the application of this fat-controlling and weight-loss functional drink in the field of slimming, indicating that it helps people lose weight and manage their body shape by inhibiting fat synthesis.

[0066] (3) Morphology and properties of the product composition The negative staining method is used to observe the vesicle morphology of the core active ingredient granules. The negative staining method uses phosphotungstic acid to stain the sample. Heavy metal salts will be specifically deposited around the vesicle sample, thus forming a high-contrast "negative phase" image under a transmission electron microscope, which can clearly show the outline, size and distribution characteristics of the vesicles.

[0067] Experimental samples: Core active ingredient granules prepared in Example 1 and core active ingredient granules prepared in Comparative Example 3; Reagents: 2% phosphotungstic acid solution (pH 6.9), deionized water, anhydrous ethanol Consumables: Copper mesh (200-300 mesh, coated with Formvar or carbon film), tweezers, filter paper, dropper Equipment: Hitachi HT-7800 transmission electron microscope (Japan).

[0068] The testing method is as follows: The core active ingredient granules were dispersed in sterile PBS to obtain a granule solution with a concentration of 0.5 mg / mL; 1 mL of the granule solution was filtered through a 0.22 μm filter membrane to remove large particulate impurities, resulting in a solution containing EGCG vesicles. Use a microdropper to draw 5 μL of EGCG solution containing vesicles and slowly add it dropwise to the center of the carbon film on the copper mesh; Use filter paper to absorb excess sample solution from the edge of the copper mesh, immediately add 5 μL of 2% phosphotungstic acid solution to cover the entire membrane surface, stain for 1 minute, absorb the staining solution again with filter paper, and rinse 3 times with deionized water to remove residual staining solution. Place the copper mesh in a dust-free environment to air dry naturally. Turn on the Hitachi HT-7800 transmission electron microscope (TEM). Following the operating procedures, complete the vacuuming and optical path calibration. Load the prepared copper mesh into the sample holder and place it into the TEM sample chamber. Adjust the focus, brightness, and contrast to clearly observe the morphology, size, and distribution of the vesicles, and take TEM images. (TEM images are shown below.) Figure 5 As shown in the figures, the upper figure corresponds to Example 1, and the lower figure corresponds to Example 3. It can be seen that both core active ingredient granules exhibit clearly defined vesicle structures with complete structures and uniform morphology. The vesicles in the core active ingredient granules of the example have larger diameters.

[0069] The specific embodiments described above further illustrate the purpose, technical solution, and beneficial effects of the present invention. It should be understood that the above descriptions are merely specific embodiments of the present invention and are not intended to limit the present disclosure. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

Claims

1. A fat-reducing and fat-preventing composition containing vesicular EGCG and fermented red ginseng, characterized in that, It includes a core active ingredient, an active additive ingredient, and an auxiliary active ingredient. The raw materials for the core active ingredient include EGCG vesicles and red ginseng fermentation liquid. The active additive ingredient is fermented red ginseng powder. The auxiliary active ingredients include coffee powder, medium-chain triglyceride powder, L-arabinose, and white kidney bean extract.

2. The lipid-reducing and lipid-blocking composition containing vesicular EGCG and fermented red ginseng according to claim 1, characterized in that, The mass ratio of the core active ingredient, the active additive ingredient, and the auxiliary active ingredient is 1:0.5~1:2~4.

3. A method for preparing the fat-reducing and fat-anti-lipid formation composition containing vesicular EGCG and fermented red ginseng as described in claim 1, characterized in that, include: Step 1: Provide fermented red ginseng powder and red ginseng fermentation liquid; Step 2: Combine EGCG vesicles with red ginseng fermentation liquid to form core active ingredient granules; Step 3: Mix the core active ingredient granules, active additives and auxiliary active ingredients to obtain a fat-reducing and fat-resistant composition containing EGCG vesicles and fermented red ginseng.

4. The method according to claim 3, characterized in that, The preparation method of the red ginseng fermentation liquid includes: dispersing red ginseng powder in water, fermenting it after enzymatic hydrolysis with a compound enzyme to obtain red ginseng fermentation liquid; the preparation method of the fermented red ginseng powder includes: spray drying the red ginseng fermentation liquid to obtain fermented red ginseng powder.

5. The method according to claim 4, characterized in that, The mass ratio of red ginseng powder, water, and compound enzyme is (1~2):(6~8):(0.1~0.15); the compound enzyme is cellulase and pectinase, and the mass ratio of cellulase and pectinase is (0.05~0.08):(0.05~0.07); and / or, the enzymatic hydrolysis temperature of the compound enzyme is 48℃~52℃, and the hydrolysis time is 5h~6h; and / or, the fermentation includes mixing the system to be fermented with lactic acid bacteria, first sealing and stirring, and then letting it stand, wherein the lactic acid bacteria are *Lactobacillus plantarum* and *Lactobacillus fermentatus*, the mass of *Lactobacillus plantarum* is 8%~9% of the mass of water, and the mass of *Lactobacillus fermentatus* is 8%~9% of the mass of water.

6. The method according to claim 5, characterized in that, The sealing and stirring time is 15 minutes, the fermentation temperature is 36.5℃~37.5℃, the standing time is 16h~24h, and the fermentation endpoint is a system pH of 3.50~3.

90.

7. The method according to claim 3, characterized in that, Step 2, combining EGCG vesicles with the fermented red ginseng to form core active ingredient granules, specifically includes: adding EGCG, maltodextrin and β-cyclodextrin to the red ginseng fermentation broth, mixing well, pre-filtering and double-layer filtration to obtain a mixed solution, and spray drying to obtain core active ingredient granules.

8. The method according to claim 7, characterized in that, The pre-filter membrane has a pore size of 0.45 μm, and the double-layer filter membrane has pore sizes of 0.45 μm and 0.22 μm respectively; and / or, the mass ratio of the red ginseng fermentation liquid, EGCG, maltodextrin and β-cyclodextrin is (87~82):(4~6):(4~5):(5~7).

9. The method according to claim 3, characterized in that, Step 3: Mix the core active ingredient granules, active additives, and auxiliary active ingredients to obtain a fat-reducing and fat-resistant composition containing EGCG vesicles and fermented red ginseng, specifically including: (1) Mix the core active ingredient granules and the active additives to obtain mixed granules; (2) Add the mixed granules into the auxiliary active ingredients and mix well to obtain a fat-reducing and fat-resistant composition containing EGCG vesicles and fermented red ginseng.

10. The method according to claim 8, characterized in that, The mass ratio of coffee powder, medium-chain triglyceride powder, L-arabinose, and white kidney bean extract in the auxiliary active ingredients is (6~7):(4~6):(3~5):(3~5).

Images